MJardin Group Competitors

MJardin Group (OTCMKTS:MJARF) and Abacus Health Products (OTCMKTS:ABAHF) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, risk and valuation.

Valuation & Earnings

This table compares MJardin Group and Abacus Health Products' top-line revenue, earnings per share (EPS) and valuation.

Profitability

This table compares MJardin Group and Abacus Health Products' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and price targets for MJardin Group and Abacus Health Products, as provided by MarketBeat.

MJardin Group currently has a consensus target price of $0.10, indicating a potential upside of 69.78%. Given MJardin Group's higher possible upside, equities analysts clearly believe MJardin Group is more favorable than Abacus Health Products.

Summary

MJardin Group beats Abacus Health Products on 1 of the 1 factors compared between the two stocks.

Acreage (OTCMKTS:ACRGF) and MJardin Group (OTCMKTS:MJARF) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.

Profitability

This table compares Acreage and MJardin Group's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Acreage and MJardin Group's gross revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Acreage and MJardin Group, as provided by MarketBeat.

Acreage presently has a consensus price target of $8.4333, suggesting a potential upside of 204.45%. MJardin Group has a consensus price target of $0.10, suggesting a potential upside of 69.78%. Given Acreage's stronger consensus rating and higher probable upside, equities analysts plainly believe Acreage is more favorable than MJardin Group.

Summary

Acreage beats MJardin Group on 3 of the 3 factors compared between the two stocks.

MJardin Group (OTCMKTS:MJARF) and Applied Biosciences (OTCMKTS:APPB) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, earnings and institutional ownership.

Analyst Recommendations

This is a summary of recent recommendations for MJardin Group and Applied Biosciences, as provided by MarketBeat.com.

MJardin Group presently has a consensus target price of $0.10, suggesting a potential upside of 69.78%. Given MJardin Group's higher probable upside, equities analysts clearly believe MJardin Group is more favorable than Applied Biosciences.

Valuation & Earnings

This table compares MJardin Group and Applied Biosciences' gross revenue, earnings per share and valuation.

Profitability

This table compares MJardin Group and Applied Biosciences' net margins, return on equity and return on assets.

Summary

MJardin Group beats Applied Biosciences on 1 of the 1 factors compared between the two stocks.

MJardin Group (OTCMKTS:MJARF) and Ayr Strategies (OTCMKTS:AYRSF) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings and analyst recommendations.

Profitability

This table compares MJardin Group and Ayr Strategies' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares MJardin Group and Ayr Strategies' top-line revenue, earnings per share (EPS) and valuation.

Analyst Ratings

This is a breakdown of recent recommendations for MJardin Group and Ayr Strategies, as provided by MarketBeat.

MJardin Group presently has a consensus target price of $0.10, indicating a potential upside of 69.78%. Ayr Strategies has a consensus target price of $34.8571, indicating a potential upside of 63.96%. Given MJardin Group's higher possible upside, equities research analysts clearly believe MJardin Group is more favorable than Ayr Strategies.

Summary

Ayr Strategies beats MJardin Group on 2 of the 3 factors compared between the two stocks.

MJardin Group (OTCMKTS:MJARF) and Can B (NASDAQ:CANB) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, valuation and risk.

Valuation and Earnings

This table compares MJardin Group and Can B's top-line revenue, earnings per share (EPS) and valuation.

Analyst Ratings

This is a summary of recent ratings and price targets for MJardin Group and Can B, as provided by MarketBeat.

MJardin Group currently has a consensus target price of $0.10, suggesting a potential upside of 69.78%. Given MJardin Group's higher possible upside, equities research analysts plainly believe MJardin Group is more favorable than Can B.

Profitability

This table compares MJardin Group and Can B's net margins, return on equity and return on assets.

Summary

MJardin Group beats Can B on 1 of the 1 factors compared between the two stocks.

Cansortium (OTCMKTS:CNTMF) and MJardin Group (OTCMKTS:MJARF) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings for Cansortium and MJardin Group, as reported by MarketBeat.

Cansortium currently has a consensus price target of $1.20, suggesting a potential upside of 11.11%. MJardin Group has a consensus price target of $0.10, suggesting a potential upside of 69.78%. Given MJardin Group's higher probable upside, analysts clearly believe MJardin Group is more favorable than Cansortium.

Earnings and Valuation

This table compares Cansortium and MJardin Group's revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Cansortium and MJardin Group's net margins, return on equity and return on assets.

Summary

Cansortium beats MJardin Group on 2 of the 3 factors compared between the two stocks.